SINGAPORE — The Health Sciences Authority has approved multiple applications for private hospitals or clinics to bring in the Chinese-made Sinopharm vaccine via the Special Access Route scheme., the authority on Friday said that 11 such applications, including for clinics under IHH Healthcare Singapore, have been approved as of Wednesday.
"The risks of using COVID-19 vaccines approved under SAR are fully borne by the doctor and vaccine recipient," the HSA added. The Sinopharm is the second Chinese-made vaccine to be made available in Singapore via the SAR scheme after Sinovac's CoronaVac vaccine.are not included in Singapore's national vaccination numbers
. As of Wednesday, 95,029 doses of the China-made vaccine have been administered to 71,810 individuals. Under the SAR scheme for COVID-19 vaccines, private healthcare providers can apply to the HSA to bring in COVID-19 vaccines that are listed on the World Health Organisation’s Emergency Use Listing, for use by the doctors of that healthcare provider on patients under their care for specified needs.Currently, only the Pfizer-BioNTech/Comirnaty and Moderna vaccines are part of Singapore's national vaccination programme.
Ask yourself why Xi Jinping himself hasn't taken Sinovac or Sinopharm. Speaks volumes
S'pore made it clear that unless those allergic to Pfizer/Moderna, they are to pay & responsible for hospital stays for their 'preferred' brands. This will allows more to be vaccinated yet without incurring cost + out of the blames for not approving these 'preferred' brands
Singapore smart. Few Singaporeans except the 450K Chinese National working in S'pore will want Sinovac. They 'sold' their 200K sinovac stock purchased by a bet, getting their money back instead of donating them, Sinopharm is a similar alternative. This time no money spent.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: YahooSG - 🏆 3. / 71 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »